Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...